Actively Recruiting
Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2024-07-17
14
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Bronchiolitis obliterans (BO) is the well-known manifestation of the chronic pulmonary graft-versus-host disease(GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). The pathophysiology of BO is, however, poorly known. The available data strongly support the role of respiratory viruses, in particular paramyxoviruses (parainfluenzae virus (PIV), respiratory syncytial virus, metapneumovirus). It is likely that the alloimmune response triggered by the respiratory virus is inadequate and leads to the peribronchiolar fibrotic process. The objective is to analyze the kinetics of profiles of the blood and respiratory host responses resulting from a high or low parainfluenza respiratory infection, in order to evaluate if the occurrence of a BO is associated with a specific signature We will evaluate the predictive signature of a BO after a parainfluenza virus infection by characterizing the differences between the patients evolving and those not evolving to a BO at 2 months after the infection.
CONDITIONS
Official Title
Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults who received hematopoietic stem cell transplantation less than two years ago
- Availability of respiratory function tests before infection
- Confirmed parainfluenza virus respiratory infection by PCR in upper or lower respiratory tract
- Respiratory infection symptoms for 5 days or less
- Signed informed consent
You will not qualify if you...
- Presence of any respiratory virus infection other than parainfluenza virus
- Co-infections with other respiratory viruses
- Bacterial or fungal respiratory infections
- Treatment with ribavirin, oseltamivir, or other antiviral drugs active against respiratory viruses
- Not affiliated with or beneficiary of a social security system
- Being deprived of liberty or under protection
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Saint Louis
Paris, Île-de-France Region, France, 75010
Actively Recruiting
Research Team
D
David Michonneau, MD PhD
CONTACT
J
Jérôme Lambert, MD PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here